Dr. Stambler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
275 Collier Rd NW
Ste 500
Atlanta, GA 30309Phone+1 216-844-8500Fax+1 404-351-5983
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1987 - 1990
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1987
- Duke University School of MedicineClass of 1984
Certifications & Licensure
- GA State Medical License 2014 - 2026
- OH State Medical License 1998 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Clinical Cardiac Electrophysiology
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation Start of enrollment: 2019 Apr 24
Publications & Presentations
PubMed
- Self-Administered Etripamil Nasal Spray Relieved Symptoms, Decreased Heart Rate, and Reduced Medical Interventions During Atrioventricular Nodal-Dependent Paroxysmal S...Bruce S Stambler, Benoit Coutu, James E Ip, Blandine Mondésert, A Shekhar Pandey
Circulation. Arrhythmia and Electrophysiology. 2024-11-27 - Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion.James E Ip, Benoit Coutu, Peter A Noseworthy, Maria L Parody, Farhad Rafii
Journal of the American College of Cardiology. 2024-05-21 - Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast-Acting, Nondihydropyridine Calcium Channel Blocker.James E Ip, Douglas Wight, Corinne Seng Yue, David Nguyen, Francis Plat
Clinical Pharmacology in Drug Development. 2024-04-01
Authored Content
- Nasal Spray Shows Potential for Quickly Treating ArrhythmiaJuly 2018
Press Mentions
- Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022October 25th, 2022
- Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular TachycardiaOctober 17th, 2022
- Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate UpdateAugust 10th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: